Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986453 |
| Synonyms | |
| Therapy Description |
BMS-986453 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting TNFRSF17 (BCMA) and GPRC5D, which potentially induces toxicity in TNFRSF17 (BCMA) and GPRC5D-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986453 | BMS986453|BMS 986453 | GPRC5D Immune Cell Therapy 4 TNFRSF17 Immune Cell Therapy 27 | BMS-986453 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting TNFRSF17 (BCMA) and GPRC5D, which potentially induces toxicity in TNFRSF17 (BCMA) and GPRC5D-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06153251 | Phase I | BMS-986453 Cyclophosphamide + Fludarabine | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | 0 |